Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database
about
Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best PracticeDrug-induced liver injury: Advances in mechanistic understanding that will inform risk management.Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review.Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease.Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors.Drug-induced liver injury: Do we know everything?Clinical Trials and a View Toward the Future of ADPKD.Drug-Induced Liver Injury: Highlights from a Review of the 2015 Literature.Ten pitfalls in the proper management of patients with hyponatremia.Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial.Drug rechallenge following drug-induced liver injury.Recent advances in autosomal-dominant polycystic kidney disease.Liver involvement in kidney disease and vice versa.Human Sulfotransferases Enhance the Cytotoxicity of Tolvaptan.Inhibition of Human Hepatic Bile Acid Transporters by Tolvaptan and Metabolites: Contributing Factors to Drug-Induced Liver Injury?Age-Related Alterations in Blood Biochemical Characterization of Hepatorenal Function in the PCK Rat: A Model of Polycystic Kidney Disease.Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 TrialVasopressin Receptor Antagonists in Hyponatremia: Uses and Misuses.Effect of tolvaptan in a patient with autosomal dominant polycystic kidney disease after living donor liver transplantation.Long-Term Vaptan Treatment of Idiopathic SIADH in an OctogenarianLong-term safety profile of tolvaptan in autosomal dominant polycystic kidney disease patients: TEMPO Extension Japan Trial.Green mamba peptide targets type-2 vasopressin receptor against polycystic kidney disease.miR-122 Release in Exosomes Precedes Overt Tolvaptan-Induced Necrosis in a Primary Human Hepatocyte Micropatterned Coculture Model.European ADPKD Forum multidisciplinary position statement on autosomal dominant polycystic kidney disease care: European ADPKD Forum and Multispecialist Roundtable participants.Approach to hyponatremia according to the clinical setting: Consensus statement from the Italian Society of Endocrinology (SIE), Italian Society of Nephrology (SIN), and Italian Association of Medical Oncology (AIOM).Is the light at the end of the tunnel nigh? A review of ADPKD focusing on the burden of disease and tolvaptan as a new treatment.Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations.Editor's Highlight: Candidate Risk Factors and Mechanisms for Tolvaptan-Induced Liver Injury Are Identified Using a Collaborative Cross Approach.Lkb1 deficiency confers glutamine dependency in polycystic kidney disease.Management Strategies and Outcomes for Hyponatremia in Cirrhosis in the Hyponatremia Registry
P2860
Q26767011-A402B173-CB48-46CB-A9B0-0A27E02057F1Q30241050-B72CE02D-C542-4B9C-801A-09FB5BD9DA72Q30277969-1126FF5C-AB06-4566-9FA8-5B0404CC2060Q33873132-8CBD3307-780F-4744-BF61-C15B57AFFD27Q37564187-608A7088-4C96-476D-BC79-B459FEBBF1C5Q37748005-99BD997A-6776-4FE7-9D51-9C8F7A298AE8Q38812543-4CF1DC8B-F3BA-4540-8943-6EDA519397F3Q38824550-385D042E-DC1C-41F6-9C54-28804BE5FA5AQ38827652-DE5C92CF-D18A-4C36-AFBA-D81639AC822FQ38853071-2635AF55-9FA8-42A5-90A0-73050DA5BEBCQ38906878-E9FE0843-0C4F-4887-B250-6B7514D52137Q38935264-E3FBCE66-322F-4836-951B-2D6A0E5EE5DFQ39395392-DDA60AAC-7953-41A0-864D-B2C87136F1F0Q40218518-EB9108B5-41D2-4A15-8D9A-867D60A9E68DQ40386706-E4DEBC5F-0A83-4977-BF25-324AB59BBB59Q40390494-BDC98B59-871F-474E-AB9F-3637E7C98BC8Q41076909-C2791821-EDEA-4706-A979-91728DCC64E1Q41534781-0B9D3AB6-FFEC-4E43-BEE5-03EC6E2AAB67Q42290043-2A0255B1-6C1F-4691-B32A-269D7631FC76Q42370040-BA622133-886C-4DEB-AA3F-B295A2A8071FQ46081472-219A1288-F418-4A6F-A78B-40261CA12EBAQ47141485-7BA5FF83-5E9A-4115-A4A2-AFBE063636DEQ47446885-C47EDAB6-0179-4317-A5D9-48CA88C70652Q47564027-CB6A81DC-56B1-4D00-8705-D832569D1959Q49893436-FCDF6BC6-EA59-4616-A94A-A6F44B14E3A8Q50024807-8295F248-7E97-4EF4-8823-3C1012859B22Q50048323-7008EC52-C42B-4E0D-B802-5FEF0B0F32FCQ51172729-32A0D3C4-35C3-4941-A172-DAF9095F0081Q52730232-C40BF1E1-D73E-46A7-8F4C-B87BD88A3860Q58548822-F83B8B87-B72E-43E0-8993-4C42526ADBF3
P2860
Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Clinical Pattern of Tolvaptan- ...... is of Clinical Trials Database
@ast
Clinical Pattern of Tolvaptan- ...... is of Clinical Trials Database
@en
type
label
Clinical Pattern of Tolvaptan- ...... is of Clinical Trials Database
@ast
Clinical Pattern of Tolvaptan- ...... is of Clinical Trials Database
@en
prefLabel
Clinical Pattern of Tolvaptan- ...... is of Clinical Trials Database
@ast
Clinical Pattern of Tolvaptan- ...... is of Clinical Trials Database
@en
P2093
P2860
P1433
P1476
Clinical Pattern of Tolvaptan- ...... is of Clinical Trials Database
@en
P2093
Christopher A Zimmer
Dan M Smotzer
David H Alpers
Frank S Czerwiec
Holly Krasa
Jaime D Blais
James H Lewis
John Ouyang
Neil Kaplowitz
Paul B Watkins
P2860
P2888
P304
P356
10.1007/S40264-015-0327-3
P577
2015-07-19T00:00:00Z